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ABSTRACT:  
The aim of this study was to compare cytokine expression on both gene and protein levels in 
acute and chronic phase of HIV type 1 (HIV-1) infection. Thirty four patients were enrolled 
for cytokine expression analysis on protein level in acute and chronic stage of HIV-1 
infection. Using PCR array technology, expression of 84 cytokine genes was measured in 3 
patients in acute and 3 patients in chronic stage of HIV-1 infection. Bead-based cytometry 
was used to quantify levels of Th1/Th2/Th9/Th17/Th22 cytokines. The results showed 
statistically significant increase of 13 cytokine gene expression (cd40lg, csf2, ifna5, il12b, 
il1b, il20, lta, osm, spp1, tgfa, tnfsf 11, 14 and 8) and downregulation of the il12a expression 
in chronic HIV type 1 infection. Concentrations of IL-10, IL-4 and TNF-α were increased in 
the acute HIV type 1 infection when compared to control group. During chronic HIV type 1 
infection there was an increase of IL-10, TNF-α, IL-2, IL-6, IL-13 and IL-22 levels when 
compared to control group. Comparison of cytokine expression between two stages of 
infection showed a significant decrease in IL-9 concentration. This study showed changes in 
cytokine profiles on both gene and protein levels in different stages of HIV-infection. 
KEYWORDS: HIV-1; biological response modifiers; Th1/Th2 cytokine shift; acute HIV-1 
infection; chronic HIV-1 infection 
HIGHLIGHTS:  
 HIV-1 infection causes cytokine profile changes on both gene and protein levels 
 In chronic HIV-1 infection 13 cytokine-encoding genes were overexpressed 
 Levels of IL-9 were significantly reduced with the progression of HIV-1 infection 
 The progression of HIV-1 infection is not associated with  Th1 to Th2 shift  
 
1. INTRODUCTION:  
Infection with human immunodeficiency virus type 1 (HIV-1) is characterized by a 
continuous depletion of helper CD4+ T-cells and hyperactivation of the immune system [1] 
and [2]. The course of infection can be classified into several stages. The eclipse phase is a 
period between 1-2 weeks post infection when the virus replicates and spreads from the origin 
of infection to different tissues and organs [3]. Rapid increase in viremia and simultaneous 
decrease in the population of CD4+ T-cells (particularly in gut-associated lymphoid tissue, 
GALT), mark the onset of acute stage of infection [4] and [5]. According to the Fiebig's score, 
acute HIV-1 infection can be classified into six stages, based on the serological and molecular 
assays for detection of p24 antigen, virus-specific antibodies and HIV-1 RNA [6] and [7]. 
Upon activation of host-specific cellular immunity, HIV-1 infection progresses to the stage of 
clinical latency with usually low level viremia for long periods of time (up to 20 years). High 
level of immune activation is also present during chronic infection, as illustrated by increased 
expression of activation markers CD38, HLA-DR and Ki67 [8]. In time, constant viral 
replication and immune activation cause further decrease in CD4+ T-cell counts, immune 
system loses control over infection leading to opportunistic infections, malignancies and death 
of untreated individuals [3]. Cytokines are biological response modifiers synthesized by cells 
of innate and adaptive immunity that are important in intercellular communication and 
regulation of immune reactions [9], [10], [11] and [12]. Effector functions of CD4+ T-cells 
depend on cytokine immunity. Naive CD4+ T-cells differentiate to effector cell after 
recognition of antigenic peptides bound to MHC Class II molecules expressed on antigen-
presenting cells [13]. Depending on cytokine environment, CD4+ T-cells differentiate into 
Th1, Th2, Th9, Th17, Th22 as well as regulatory (Treg) and follicular (Tfh) cell populations 
that have different biological functions [14]. The role of cytokines in the pathogenesis of 
HIV-disease, particularly in the context of Th cytokine profiles, has not been fully elucidated. 
In acute HIV infection, increasing viral replication induces the synthesis of various cytokines 
[15]. Concentrations of IFN-α and IL-15 increase within the 5 days following the onset of 
measurable plasma viremia. Subsequently, increased concentrations of TNF-α, MCP-1,  IL-6, 
IL-8, IL-18 and IFN-γ are also detected [16]. Cytokines synthesized in early HIV-1 infection 
can have a complex effect on the host. They can accelerate the immune response against the 
virus [17], while simultaneously, cytokine activity amplifies the population of target cells for 
HIV infection by activating CD4+ T-cells. In chronic HIV infection, elevated concentrations 
of proinflammatory cytokine TNF-α and its receptor TNF-RII indicate long-term 
inflammation in infected persons [18] and [19].  
Literature data on the cytokines corresponding to the effector profiles of CD4+ T-cells 
are scarce. In 1993, Clerici and Shearer introduced a hypothesis that shift from Th1 to Th2 
cytokine profile is crucial for the immunopathogenesis of HIV-disease [20] but in vivo and ex 
vivo studies by other groups did not support these findings [21] and the issue remains 
controversial. In untreated HIV-infected individuals, depletion of Th17 cells can be observed 
in the gut mucosa and is linked to the loss of integrity of gut mucosal barrier [22]. In HIV-
infected children, Ndhlovu et al found a positive correlation between viremia and decrease in 
Th17 cell count [23]. Th22 cells synthesize IL-22, a cytokine responsible for the maintenance 
of epithelial barrier integrity. In HIV-1 infection, Th22 cells are depleted leading to the 
systemic immune activation and loss of mucosal immunity [24].  
The aim of this study was to compare the expression of genes coding for cytokines and 
other biological response modifiers in acute and chronic HIV infection and to analyze the 
patterns of Th1, Th2, Th9, Th17 and Th22 cytokines in the plasma of HIV-infected persons at 
the acute and chronic stage of infection.  
 
2. METHODS:  
2.1. Subjects 
The study is a retrospective analysis of cytokine expression on both gene and protein levels  
in HIV-infected individuals receiving clinical care at the Croatian Reference Center for 
HIV/AIDS of the University Hospital for Infectious Diseases (UHID) in Zagreb, Croatia. 
HIV-infected pregnant women, minors and HIV-infected individuals with intercurrent disease 
were excluded from the study. Thirty four patients were enrolled for cytokine expression 
analysis on protein level in acute and chronic phase of HIV-1 infection. Cytokine gene 
expression was determined in 6 patients, 3 patients were in acute and 3 patients were in the 
chronic stage of HIV-infection. As a control group, 22 HIV-negative individuals were 
enrolled in the study. Ethics committees at the UHID and Faculty of Medicine approved the 
study and all subjects signed a consent form. 
2.2. Study design 
Cytokine expression on protein level in acute and chronic stage of HIV-1 infection was 
determined in 3 time points. The first time point represents plasma samples obtained from 
HIV-infected individuals with acute infection. Plasma samples from the same patients were 
also collected after 6 and 12 months, respectively (second and third time point).  
2.3. Immune and virological monitoring 
HIV-1 RNA quantification and absolute CD4+ T cell count data were extracted from the 
database of Department of  molecular diagnostics and flow cytometry at UHID on dates 
corresponding the samples used for cytokine expression analysis.  
HIV-1 RNA quantification was performed by using COBAS AmpliPrep/COBAS TaqMan 
HIV-1 Test (Roche Diagnostics, Manheim, Germany) as recommended by the manufacturer.  
Absolute CD4+ T cell count was determined using flow cytometer Cytomics FC500 
(Beckman Coulter, Brea, California, USA). Periferal blood was stained with fluorochrome-
conjugated antibodies CD45-FITC/CD4-RD-1/CD8-ECD/CD3-PC-5 (Beckman Coulter) and   
quantification reagent Flow-Count Fluorospheres (Beckman Coulter) was used to obtain 
absolute CD4+T cell count. 
 
2.4. Bead-based cytometry for cytokine levels analysis 
To determine the concentrations of 13 cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, 
IL-10, IL-12 p70, IL-13, IL-17A, IL-22 and TNF-α) in plasma samples Human 
Th1/Th2/Th9/Th17/Th22 13plex Kit FlowCytomix (eBioscience, San Diego, California, 
USA) was used according to the manufacturer`s instructions. In brief, this test uses beads 
coated with antibodies specific for each of 13 cytokines to be detected. They are mixed with 
25 µl of plasma samples. After incubation, biotin-conjugated second antibody is added and 
the presence of analyzed cytokine is detected using streptavidin-phycoerithrin that binds to 
the biotin conjugate and emits fluorescent signal. Detection process is carried out on flow 
cytometer Cytomix FC500 (Beckman Coulter) and Forward Scatter measurements were 
collected at 1-8°. Obtained results were processed using FlowCytomixPro software to 
determine cytokine concentration.  
2.5. PCR array technology for cytokine gene expression analysis 
Peripheral blood was collected in PAXgene RNA tube (PreAnalytiX, Hombrechtikon, 
Switzerland) and RNA was isolated using PAXgene RNA Kit (PreAnalytix) according to the 
manufacturer`s instructions. Quality and concentration of isolated RNA were tested and 
cDNA was synthesised using QIAGEN RT
2
 First Strand Kit (QIAGEN, Hilden, Germany) 
following manufacturer`s instructions. Prepared cDNA was added to the RT2 SYBR Green 
qPCR Master Mix (QIAGEN) and alliquotted on 96-well plate of  RT
2
 Profiler PCR Array 
Human Common Cytokines (QIAGEN). Array contains a panel of 96 primer sets of that 84 
specific for researched cytokine genes, 5 housekeeping genes and 3 RNA and PCR quality 
controls. Expression of following genes was determined: group of interferon genes (IFNA1, 
IFNA2, IFNA4, IFNA5, IFNB1, IFNG), interleukin genes (IL-10, IL-11, IL-12A, IL-12B, IL-
13, IL-15, IL-16, IL-17A, IL-17B, IL-17C, IL-18, IL-19, IL-1A, IL-1B, IL-1RN, IL-2, IL-20, 
IL-21, IL-22, IL-23A, IL-24, IL-25 (IL-17E), IL-27, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
TXLNA (IL-14)), growth factors (CNTF, CSF1 (MCSF), CSF2 (GM-CSF), CSF3 (GCSF), 
FIGF (VEGFD), LEFTY2 (EBAF), LIF, NODAL, OSM, PDGFA, TGFA, THPO, VEGFA), 
TGF-β family (BMP1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, GDF2 (BMP9), GDF5 
(CDMP-1), GDF9, INHA, INHBA, MSTN (GDF8), TGFB1, TGFB2, TGFB3), TNF family 
(CD40LG (TNFSF5), CD70 (TNFRSF7), FASLG (TNFSF6), LTA (TNFB), LTB, TNF, 
TNFRSF11B, TNFSF10 (TRAIL), TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, 
TNFSF4 (OX40L), TNFSF8) and other cytokines (ADIPOQ, FAM3B, SPP1 (Osteopontin)). 
PCR reactions were carried out in a ABI 7500 Standard (Applied Biosystems, Foster City, 
California, USA) under given conditions: 10 min on 95°C, 40 cycles for 15 s on 95°C and 1 
min on 60°C. Calculations and analysis of Ct values and dissociation curves for all PCR 
reaction were made using 7500 System SDS Software v1.4.0 (Applied Biosystems). Data 
analysis was performed using RT2 Profiler PCR Array Data Analysis v3.5 
(http://www.sabiosciences.com/pcrarraydataanalysis.php). Volcano plot was created to 
visualize and identify significant gene expression changes. 
 
 
2.6. Statistical analysis 
Statistical analysis was performed using SAS v9.3 software (SAS Institute, Cary, North 
Carolina, USA). Variables with non-normal distributions were described with medians and 
interquartile ranges.  Independant groups were compared with the Fisher`s exact test. Within 
the same group of examinees Wilcoxon signed rank test was used. Relative changes in gene 
expression were calculated using ΔΔCt method and the differences between gene expression 
in acute and chronic HIV-1 infection were compared with the Student`s t-test. Statistical 
significance was set at P ˂0.05 
 
3. RESULTS: 
3.1. Comparison of cytokine gene expression in acute and chronic stage of HIV-1 
infection 
Cytokine gene expression was compared in six HIV-infected individuals, three of them were 
in the acute and three in chronic stage of HIV-1 infection. Of 84 analyzed genes, 29 genes 
were overexpressed in chronic stage when compared to the acute stage of HIV-1 infection. 
Statistically significant gene expression increase between two stages of infection was noted in 
13 genes (Table 1). During chronic stage of HIV-1 infection 4 genes were downregulated and 
for one of them, il12a, this decrease in expression was statistically significant (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Overexpressed genes in chronic compared to the acute stage of HIV-1 infection 
Gene symbol Fold regulation P-value 
BMP3 3.893 0.271 
BMP4 2.949 0.131 
BMP6 2.054 0.609 
CD40LG 2.472 0.031 
CSF2 3.067 0.015 
FAM3B 3.138 0.481 
IFNA5 3.502 0.026 
IL12B 2.123 0.003 
IL17A 2.025 0.158 
IL1A 3.253 0.419 
IL1B 2.869 0.049 
IL20 4.833 0.017 
IL24 2.156 0.157 
IL4 3.312 0.256 
IL8 3.601 0.073 
INHBA 2.077 0.225 
LTA 2.249 0.005 
LTB 2.733 0.069 
OSM 2.141 0.025 
PDGFA 2.499 0.372 
SPP1 47.099 0.045 
TGFA 2.857 0.045 
TGFB2 5.405 0.146 
TNF 2.651 0.225 
TNFSF11 5.030 0.009 
TNFSF13 2.843 0.165 
TNFSF14 2.263 0.042 
TNFSF4 2.255 0.236 
TNFSF8 2.386 0.047 
Gene symbols in bold represent genes with statistically significant increase in expression in 
chronic compared to the acute stage of HIV-1 infection. Expression of 84 cytokine genes was 
measured in 3 patients in acute and 3 patients in the chronic phase of HIV-1 infection. Gene 
symbols: BMP3 (Bone morphogenic protein 3), BMP4 (Bone morphogenic protein 4), BMP6 
(Bone morphogenic protein 6), CD40LG (CD40 ligand), CSF2 (Colony stimulating factor 2), 
FAM3B (family with sequence similarity 3, member B), IFNA5 (Interferon alpha 5), IL12B 
(Interleukin 12, subunit β), IL17A (Interleukin 17, subunit α), IL1A (Interleukin 1, subunit 
α), IL1B (Interleukin 1, subunit β), IL20 (Interleukin 20), IL24 (Interleukin 24), IL4 
(Interleukin 4), IL8 (Interleukin 8), INHBA (Inhibin beta A), LTA (Lymphotoxin α),  LTB 
(Lymphotoxin β), OSM (Oncostatin M), PDGFA (Platelet-derived growth factor α 
polypeptide), SPP1 (Secreted phosphoprotein 1), TGFA (Transforming growth factor α), 
TGFB2  (Transforming growth factor β2), TNF (Tumor necrosis factor), TNFSF11 (Tumor 
necrosis factor superfamily, member 11), TNFSF13 (Tumor necrosis factor superfamily, 
member 13), TNFSF14 (Tumor necrosis factor superfamily, member 14), TNFSF4 (Tumor 
necrosis factor superfamily, member 4), TNFSF8 (Tumor necrosis factor superfamily, 
member 8).  
 
Table 2. Downregulated genes in chronic compared to the acute stage of HIV-1 infection 
Gene symbol Fold change P-value 
CD70 -3.134 0.079 
IL12A -2.259 0.021 
IL21 -4.611 0.147 
THPO -3.713 0.131 
 
   
Gene symbol in bold represent gene with statistically significant decrease in expression in 
chronic compared to the acute stage of HIV-1 infection. Expression of 84 cytokine genes was 
measured in 3 patients in acute and 3 patients in the chronic phase of HIV-1 infection. Gene 
symbols: CD70 ( Cluster of differentiation 70), IL12A (Interleukin 12, subunit α), IL21 
(Interleukin 21), THPO (Thrombopoietin). 
 FIG. 1. Volcano plot for 84 analyzed genes. On X-axis is the log2 value of the fold change 
between chronic and acute HIV-1 infection and Y-axis represents –log10 p-value. Red 
coloured circles symbolize overexpressed and green coloured circles represent 
underexpressed genes. Horizontal blue line shows threshold where P = 0.05. 
 
3.2. Th1, Th2, Th9, Th17 and Th22 cytokine levels in acute and chronic HIV-1 infection 
Concentration measurements of 13 cytokines in plasma samples obtained from 34 HIV-1 
positive individuals were conducted in 3 time points. First sample was taken during acute 
stage (T1) of HIV-1 infection. The median plasma viremia was 224 500 HIV-1 RNA 
copies/ml (IQR 74 808-883 000 HIV-1 RNA copies/ml). The median of CD4+ T cell count 
was 396 cells/μL (IQR 269-466 cells/μL). Six months after first time point concentrations of 
cytokines were again measured. In this second time point (T2) viremia decreased with median 
of 52 HIV-1 RNA copies/ml (IQR 0-30 214 HIV-1 RNA copies/ml). The median of CD4+ T 
cell count was 569 cells/μL (IQR 395-700 cells/μL). In third time point (T3), 12 months after 
first, the median plasma viremia was 31 HIV-1 RNA copies/ml (IQR 0-541 HIV-1 RNA 
copies/ml). The median of CD4+ T cell count was 593 cells/μL (IQR 457-734 cells/μL). 
Concentration measurements of 13 cytokines were also performed in 22 HIV-negative 
individuals. All the data for both HIV-infected patients as well as control group are presented 
in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Concentrations of 13 cytokines measured during acute and chronic HIV-1 infection 
in 34 individuals and 22 controls, HIV-negative group 
 Acute 
infection (T1) 
Chronic 
infection (T2) 
Chronic 
infection (T3) 
HIV-negative 
group 
Cytokine Median 
cytokine conc 
(IQR; pg/mL) 
Median 
cytokine conc 
(IQR; pg/mL) 
Median 
cytokine conc 
(IQR; pg/mL) 
Median 
cytokine conc 
(IQR; pg/mL) 
IL-12(p70) 3.7 (0.3-11.1) 3.9 (0.1-11.1) 3.4 (1.4-15.1) 0.3 (0.0-5.49) 
IFN-γ 16.7 (0.0-34.2) 0.0 (0.0-21.8) 9.2 (0.0-31.3) 1.2 (0.0-107.0) 
IL-17A 30.5 (0.0-
100.8) 
18.2 (4.4-74.2) 20.3 (1.7-
131.1) 
13.1 (0.0-
123.4) 
IL-2 34.1 (0.0-
113.6) 
32.0 (10.2-
179.6) 
47.9 (29.7-
255.6) 
3.0 (0.0-118.5) 
IL-10 12.1 (3.8-29.5) 11.2 (4.9-23.5) 12.1 (5.5-23.8) 0.5 (0.0-10.6) 
IL-9 29.6 (0.0-
220.6) 
0.6 (0.0-39.1) 5.9 (0.0-42.0) 0.3 (0.0-46.3) 
IL-22 127.6 (0.0-
215) 
141.9 (0.0-
223.7) 
156.5 (35.8-
263.5) 
0.0 (0.0-72.5) 
IL-6 1.9 (0.0-5.1) 0.7 (0.0-3.1) 1.1 (0.0-150.4) 0.0 (0.0-0.7) 
IL-13 67.1 (2.4-115) 98.5 (28.6-
121.7) 
42.5 (22.2-
136.9) 
0.0 (0.0-119.7) 
IL-4 77.6 (0.0-
252.4) 
63.6 (0.0-
164.8) 
45.8 (0.0-
150.4) 
0.3 (0.0-82.3) 
IL-5 18.2 (7.9-37.8) 21.1 (3.9-32.9) 19.8 (12.3-
30.5) 
20.7 (11.1-
86.0) 
IL-1β 38.0 (12.7-
54.4) 
32.4 (13.4-79) 39.3 (21.8-
78.8) 
17.6 (0.0-74.9) 
TNF-α 5.4 (0.0-36.2) 8.1 (0.0-16.2) 11.3 (1.7-23.4) 0.0 (0.0-5.3) 
T1- acute HIV-1 infection; T2- 6 months post acute infection; T3- 12 months post acute 
infection 
 
Our results show statistically significant increase in IL-10, IL-4 and TNF-α concentrations in 
acute stage of HIV-1 infection when compared to results obtained from healthy controls (P = 
0.008; P = 0.019; P = 0.04, respectively). When we measured cytokine concentrations in 
samples gathered six months after acute infection, levels of IL-10 and TNF-α were still 
significantly higher than those in control group and we also noticed incerase in IL-22 
concentration (P = 0.01; P = 0.037; P = 0.02, respectively). The same three cytokines, IL-10, 
TNF-α and IL-22 maintained significantly increased during chronic stage in samples collected 
12 months after acute HIV-1 infection (P = 0.003; P = 0.007 and P = 0.014, respectively). 
Besides them, in the same time period IL-2, IL-6 and IL-13 concentrations were also elevated 
when compared to the control group (P = 0.028; P = 0.046 and P = 0.037, respectively). To 
see is there a change in cytokine concentrations with the progression of HIV-1 infection we 
compared their levels among HIV-1 infected patients. The only cytokine with statistically 
significant change was IL-9 with its levels decreasing from acute to chronic stage of HIV-1 
infection (P = 0.04). When comparing cytokine levels in the same group of 34 HIV-1 infected 
individuals, but only in those with undetectable viremia at the third time point, 12 months 
after acute HIV-1 infection (N=16, 42.1%), concentrations of IL-2, IL-10, IL-22, IL-4 and 
TNF- α were significantly increased compared to controls (P = 0.024; P = 0.014; P = 0.026; P 
= 0.044 and P = 0.018, respectively). 
 
4. DISCUSSION:  
The results of this study showed increased transcriptional activity of 13 cytokine genes and 
downregulation of il12a gene in chronic versus acute HIV-1 infection. Increased serum 
concentrations of selected cytokines (IL-10, IL-4, TNF-α, IL-2, IL-6, IL-13 and IL-22) were 
found in acute and/or chronic stage of infection compared to controls. Norris et al showed 
increased concentrations of IL-10, TNF-α and IFN-γ in acute HIV infection compared to 
controls as well as a correlation between the concentration of the three cytokines and plasma 
viremia prior to seroconversion [25]. The results of our study also showed increased 
concentrations of IL-10 and TNF-α in acute HIV infection compared to controls but failed to 
demonstrate a correlation of cytokine concentrations in the serum and viremia. The difference 
in the patient selection strategies and timeline of sampling (newly diagnosed HIV-infected 
plasma donors and patients with symptomatic primary HIV-1 infection vs. patients with 
acute/recent HIV-infection) could have contributed to the observed difference in the results. 
Stacey et al analysed the changes in the cytokine profiles during the „eclipse“ phase of acute 
HIV-1 infection by analysing samples collected in 2-5 day periods [26]. Initial increase in 
IFN- α, IL-15, TNF- α, IP-10 and MCP-1 concentrations was followed by a rise in IL-6, IL-8, 
IL-10, IL-18 and IFN-γ whereas the increase in IL-4, IL-5, IL-12 and IL-22 concentrations 
was observed later. Contrary to these results indicating a „cytokine storm“ during the acute 
HIV-1 infection, the results of our study indicate increase in a limited number of cytokines 
(IL-10, IL-4 and TNF-α) in acute infection. However, it should be noted that a direct 
comparison between these results is not possible due to the differences in the sampling period 
in the two studies (eclipse phase vs. acute/recent stage of infection). Stylianou et al showed 
increasing levels of IL-10 and TNF- α level in HIV-infected patients, regardless of the stage 
of infection but with highest concentrations in patients with the most advanced disease [27]. 
Our study also demonstrated increased concentrations of IL-10 and TNF- α in HIV-infected 
patients in both acute and chronic stage of infection compared to controls. However, increased 
concentrations of these cytokines in advanced disease were not observed. The concept of a 
shift from Th1 to Th2 cytokine profiles as one of the key factors in the pathogenesis of HIV 
disease has been a controversial issue for many years. Several studies on this issue using 
diverse methodological approaches showed conflicting results [20], [21], [28] and [29]. 
According to our results, selected Th2 cytokines are already increased in acute HIV infection 
as well as during subsequent chronic stages of infection. Furthermore, the results of this study 
confirm the absence of Th1 to Th2 cytokine profile shift. IL-22 is important for the 
maintenance of the intestinal mucosa integrity. It has been previously shown that chronic HIV 
infection leads to the exhaustion of Th22 cell subset [30]. However, our study showed 
increased concentrations of IL-22 in chronic HIV-1 infection and this issue requires further 
investigations. The results of our study showed increased concentrations of IL-13 in the 
samples collected one year after acute HIV infection compared with controls. These results 
are in concordance with a study showing increased concentrations of IL-13 and IFN-γ levels 
following a decline in the viral load in HIV-infected persons [31]. IL-6 is a cytokine with 
various biological functions including B-cell stimulation, monocyte differentiation and 
induction of IL-4 producing cells. In vitro data in mitogen-stimulated CD4+ T-cells from 
HIV-infected individuals showed increased synthesis of IL-6 [32] and [33]. The results of our 
study also demonstrated increased levels of this cytokine in chronic HIV-1 infection which is 
consistent with literature data. Literature data on the role of IL-9 in HIV infection are scarce. 
Guzman-Fulgenzio et al showed that HIV/HCV coinfected persons with increased 
concentrations of IL-9 and IL-6 were less likely to achieve sustained virological response 
during double (PEG IFN-α and ribavirin) treatment of chronic hepatitis C [34]. Our study 
provides the first available evidence on a decrease in the serum concentrations of  IL-9 
between acute and chronic stage HIV-1 infection. The results of our study showed 
consistently increased concentrations of IL-12 in HIV-infected individuals compared with 
controls, irrespective of the stage of infection. Interestingly, we observed a different effect of 
HIV-infection on the levels gene expression for the two IL-12 subunits (il12a was 
downregulated whereas il12b was upregulated). Since similar observations have not been 
previously reported, these results require further investigation.  
In conclusion, this study showed important changes in the expression of Th1, Th2, Th9, Th17 
and Th22 cytokines in acute and chronic stage of HIV-infection. Increased cytokine synthesis 
during the chronic stage of infection, even in treated patients with undetectable viremia, 
suggests persistent hyperactivation of the immune system in HIV infection.  
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